comparemela.com
  1. Home
  2. Live Updates
  3. Youzhi Tong - Breaking News

Latest Breaking News On - Youzhi tong - Page 10 : comparemela.com

Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and.

United statesHong kongKintor pharmaJiangsu alphamabKintor pharmaceuticalUs food drug administrationKintor pharmaceuticalsPfizer incHong kong stock exchangeEuropean unionNational medical products administration of chinaNational medical products administrationPrnewswire kintor pharmaceutical limited pharmaPharmaceutical limitedYouzhi tongAlphamab oncology

Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and.

Kintor pharmaKintor pharmaceuticalsNational medical products administrationKintor pharmaceuticalKintor pharmaceutical limited pharmaKintor pharmaceutical limitedGreater chinaYouzhi tongPharmaceutical limited

Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and.

Kintor pharmaKintor pharmaceuticalsNational medical products administrationKintor pharmaceuticalKintor pharmaceutical limited pharmaKintor pharmaceutical limitedGreater chinaYouzhi tongPharmaceutical limited

Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and.

United statesKintor pharmaNivolumab opdivoKarl schmiederIr teamDrug administrationKintor pharmaceuticalKintor pharmaceuticalsPfizer incPrnewswire kintor pharmaceutical limited pharmaPr teamNational medical products administrationPharmaceutical limitedUnited states foodYouzhi tong

Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesKintor pharmaKintor pharmaceuticalsEuropean unionPrnewswire kintor pharmaceutical limited pharmaKintor pharmaceuticalPharmaceutical limitedYouzhi tongChief executive officerSouth americaCoronavirus pandemicPr newswireClinical trials

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.